Data was analysed using SPSS software,

p < 0.05 is significant. Data is expressed as median (Interquartile range). Results: Only 8 of the 30 patients had data to date for hsTnT post-transplant. Group 1 (n = 5) had a hsTnT of 8.2 ± 4.27 ng/L which was lower compared to Group 2 (n = 25, 53.40 ± 36.85). Median ages in Group 1 were 43.39 ± 16.17 years and 52.45 ± 15.52 years in Group 2. Group 2 hsTnT significantly decreased post transplant Z-VAD-FMK in vitro by 40.25 ± 40.14 (P = 0.036). Group 1 had no cardiac events post-transplant. However, 16% of Group 2 suffered a cardiac event in the post-transplant period. Conclusions: Basally elevated hsTnT alters significantly following transplantation and possibly identifies patients at high risk for cardiovascular events following transplantation. Larger studies need to be done to confirm this effect and consideration should

be made for a normal or low hsTnT level as an entry criterion to the decreased donor transplant waitlist. 266 SUPPORTING LEAVE FOR LIVING ORGAN DONORS SCHEME – AN INNOVATIVE FEDERAL POLICY SOLUTION TO FINANCIAL Temozolomide BARRIERS L TOY, T MATHEW, A WILSON, M LUDLOW Kidney Health Australia, Canberra, ACT, Australia Aim: Financial hardship for live donors is an issue that Kidney Health Australia (KHA) has been advocating for, both on behalf of and with, living donors, those with kidney disease, their families and carers. Background: More than 200 otherwise healthy people choose to undergo an invasive surgical procedure to become a live kidney donor every year. Those donating a kidney are subjected to out of pocket expenses for the cost of the procedure and unpaid leave often compounds their financial situation. Methods: Some international approaches focussed

on reimbursement for out of pocket medical costs – a difficult model in Hydroxychloroquine molecular weight Australia noting the differing responsibilities of Federal, State and Territory Governments. KHA focussed on a federal response by utilising an existing policy precedent from outside the health portfolio (maternity and defence force leave) and demonstrated workable budget costings for consideration. Results: In April 2013 the Federal Minister for Health, with KHA, announced a two year pilot of the scheme, commencing 1 July 2013. It covers live kidney and partial liver donation, providing access to 6 weeks paid leave at minimum wage rates. Up until 28 February 2014 there have been 90 registrations, with 36 claims already reimbursed following the donation procedure. Conclusions: Success depends on a comprehensive communication and support strategy to ensure potential donors, recipients, employers, and hospital staffs are confident in accessing the Scheme. Although modelling suggests the Scheme may pay for itself over time, the strongest justification is its potential in correcting the current burdens borne by live donors.